Purpose: Anti-CD20 monoclonal antibodies (mAb) are an important immunotherapy for B-cell lymphoma, and provide evidence that the immune system may be harnessed as an effective lymphoma treatment approach. ALT-803 is a superagonist IL-15 mutant and IL-15Ra-Fc fusion complex that activates the IL-15 receptor constitutively expressed on natural killer (NK) cells. We hypothesized that ALT-803 would enhance anti-CD20 mAbdirected NK-cell responses and antibody-dependent cellular cytotoxicity (ADCC).
Introduction
Indolent B-cell non-Hodgkin lymphomas (iNHL) represent the most common clinical group of NHLs (1) , are typically considered incurable, and the optimal approach to iNHL therapy remains unresolved (2) . Currently, immunotherapy with anti-CD20 monoclonal antibodies (mAb), alone or in combination with chemotherapy, is a standard therapy for patients with iNHL (2, 3) . However, responses are heterogeneous with some remissions lasting for years, and others a few months. While chemotherapy remains a mainstay of modern iNHL therapy, much of the toxicity of current combination regimens, including bone marrow suppression and the potential risk of secondary malignancies, results from the chemotherapy component. Recently, clinical research efforts have explored promising combinations that eliminate chemotherapy, and instead rely on doublets of therapeutic mAbs (3), survival pathway inhibitors (4) , and/or utilizing immunomodulatory drugs (5) . The goal of such a treatment paradigm is long-term disease control with minimal side effects for patients, without a requirement for cytotoxic chemotherapy or radiotherapy.
Use of anti-CD20 mAbs represents an effective, well-tolerated passive immunotherapy approach for iNHL, which may rely on several mechanisms of action including antibody-dependent cellular cytotoxicity (ADCC) to eliminate lymphoma cells (6, 7) . NK cells are one cellular mediator of ADCC, with FcgRIIIa (CD16) being a dominant cell surface activating receptor for triggering NK-cell antitumor responses (8) . The contribution of FcgRIIIa to anti-CD20 mAb responses is supported by enhanced clinical activity in patients with genetic polymorphisms that confer a higher affinity FcgRIIIa binding (9, 10) . Furthermore, studies have demonstrated in vivo NK-cell activation in the blood of patients treated with anti-CD20 mAbs (11, 12) . Second-generation anti-CD20 mAbs have been engineered to enhance the interaction between the Fc region and the low-affinity FcgRIIIa expressed on NK cells, resulting in even more potent ADCC (6) . Recently, a study has identified a correlation between killer cell immunoglobulin-like receptor (KIR) genotype and delayed progression in iNHL patients treated with mAb therapy, further implicating NK cells as an important effector for iNHL (13) . We reasoned that novel treatment approaches for iNHL that increase NK-cell ADCC in concert with anti-CD20 mAbs may result in enhanced antitumor responses without incurring serious or longterm complications that may occur with cytotoxic chemotherapy drugs.
NK cells are innate lymphoid cells that comprise 5% to 20% of human blood lymphocytes, and constitutively express a number of cytokine receptors, thereby making them amenable to cytokine-based priming in vivo (8, 14) . Stimulation through the shared IL2/15Rbg c receptor by the cytokine IL-15 has been shown to enhance NK-cell ADCC in vitro (15) , including that directed by anti-CD20 mAbs (16) . IL-15 impacts other functions, including increased cytotoxic effector molecule expression, enhanced proliferation and survival, increased motility, and costimulation of NK-cell-derived cytokines (e.g., IFNg; refs. 14, [17] [18] [19] . IL-15 is physiologically transpresented by its high-affinity IL-15Ra from the surface of accessory cells to the IL2/15Rbg c on NK cells, resulting in the activation of multiple intracellular signaling pathways, including Jak1/3 and STAT3/5, MAPK, PI3K-Akt, and mTOR kinase (19) . Approaches that utilize soluble IL-15/IL-15Ra complexes exhibit enhanced in vivo effects compared with IL-15 alone (20) (21) (22) (23) . ALT-803 is an IL-15 superagonist complex comprised of an IL-15 mutein bound to the sushi domain of IL-15Ra fused to the Fc region of IgG1 (23) (24) (25) . This results in accessory cellindependent transpresentation of IL-15, prolonged in vivo pharmacokinetics, increased in vivo biologic activity compared with IL-15, and enhanced CD8 T-cell responses in multiple myeloma mouse models (25) . Thus, we hypothesized that ALT-803 would effectively prime NK-cell ADCC against B-cell NHL in concert with anti-CD20 therapeutic mAbs, resulting in an enhanced antilymphoma innate immune response. Here, we tested this hypothesis by defining the preclinical effects of ALT-803 on NK-cell responses directed by anti-CD20 mAbs against primary B-cell lymphoma and lymphoma cell lines in vitro and in vivo.
Materials and Methods

Reagents and mice
Anti-human mAbs used were as follows: BD Biosciences: CD16 (3G8), IFNg (B27), CD69 (FN50), CD107a (H4N3); Beckman Coulter: CD56(N901), CD3(UCHT1), CD45(J.33); Invitrogen: granzyme B(GB12); and BioLegend: perforin (dG9), HLA-DR (L243). Endotoxin-free recombinant human (rh)IL-15 (CellGenix) and ALT-803 (Altor) were used for NK-cell stimulation. Clinical grade antibodies included rituximab (Genentech) and cetuximab (Bristol Myers Squibb). hOAT (humanized anti-tissue factor IgG1 antibody, Altor) also served as a control. NOD-SCIDIL2Rg À/À (NSG) mice were obtained from the Jackson Laboratory.
Fox Chase SCID (C.B-17/IcrHsd-Prkdc-scid) mice were obtained from Harlan Laboratories. All mouse experiments were performed under a Washington University ASC protocol (NSG model) or Altor BioScience IACUC (SCID model) approved protocols.
Cell lines K562 cells (ATCC, CCL-243) and Raji cells (ATCC, CCL-86) were obtained from ATCC in 2008, viably cryopreserved and stored in LN2, thawed for use in these studies, and maintained for no more than 2 months at a time in continuous culture as described (26) . Prior to our studies, the K562 cells were authenticated by confirming cell growth morphology (lymphoblast), growth characteristics, and functionally as NK-cell-sensitive targets in 2014 and 2015. Raji cells were authenticated by confirming cell growth morphology (lymphoblast), growth characteristics, phenotype of uniform expression of human CD20, and functionally as anti-CD20 mAb-opsonized targets for ADCC in 2014 and 2015. Daudi cells (ATCC, CCL-213) were obtained from ATCC in 2004, viably cryopreserved, and stored in LN2. Prior to use in these studies, the Daudi cells were authenticated in 2014 and 2015 by confirming cell growth morphology (lymphoblast), growth characteristics, phenotype of uniform expression of human CD20 by flow cytometry, and functionally as anti-CD20 mAb-opsonized targets for ADCC. Cells were cultured in R10: RPMI1640 supplemented with L-glutamine, HEPES, NEAA, sodium pyruvate, and Pen/Strep/Glutamine containing 10% FBS (Hyclone or Sigma Aldrich). Cells were washed in PBS (Hyclone) prior to mouse injections.
NK-cell purification and cell culture
Human normal donor PBMCs were obtained anonymously from platelet-apheresis donors or from OneBlood (26) . NK cells were purified using RosetteSep (StemCell Technologies) or Ficoll centrifugation and CD56 þ CD16 þ NK cell isolation kit (Miltenyi).
Cells were cultured at 3 to 5 Â 10 6 cells/mL in HAB10: RPMI1640 supplemented with L-glutamine, HEPES, NEAA, and Pen/Strep containing 10% human AB serum (Sigma-Aldrich). Cells were preactivated for 18 to 20 hours using rhIL-15 or ALT-803 as indicated. Cells were washed in HAB10 before functional assays were performed. For some experiments, cells were cultured for 48 hours in R10.
Translational Relevance
Therapeutic monoclonal antibodies (mAb) are a standard immunotherapy treatment for patients with various types of malignancy, including lymphoma. One cellular effector for therapeutic mAb-induced responses are natural killer (NK) cells, which recognize mAb-opsonized targets via the activating receptor FcgRIIIa (CD16). The IL-15 receptor is a central cytokine signal for NK-cell enhanced functionality, and physiologically the IL-15Rbg recognizes IL-15 transpresented from accessory cells via the high-affinity IL-15Ra. ALT-803 is a superagonist IL-15 mutant and IL-15Ra-Fc fusion complex that exhibits prolonged in vivo pharmacokinetics, and effectively transpresents IL-15 in the absence of accessory cells. Here we show that ALT-803 augments the in vitro and in vivo response of NK cells when directed by anti-CD20 mAbs, against lymphoma targets, in vitro and in vivo. These results provide the rationale for translating this immunotherapy combination of immunostimulation by ALT-803 and therapeutic mAbs into clinical trials for cancer patients.
Functional and proliferation assays
NK-cell functional and proliferation assays were performed as described (26, 27) . In experiments using rituximab-opsonized targets, cells were preincubated with mAbs for 30 minutes, washed, and used at the indicated E:T ratios.
Flow-based killing assays
Cytotoxicity assays were performed as described (27, 28) . Data were acquired on a Gallios flow cytometer (Beckman Coulter) and analyzed using Kaluza (Beckman Coulter) software. For the ADCC assays with Raji, target cells were preincubated with rituximab 10 mcg/mL or cetuximab 10 mcg/mL as a control in HAB10, washed, cocultured with human NK cells at the indicated E:T ratios. For the ADCC assays with Daudi, target cells were labeled with CellTrace Violet (Invitrogen) and incubated for 2 days with the indicated effectors at the indicated E:T ratios. Daudi viability was assessed by detecting PI using flow cytometry.
Patient samples
Primary lymph node lymphoma cells were collected under the Institutional Review Board-approved Washington University Lymphoma Banking Protocol (2011-08251) after informed consent. A single-cell suspension was generated by mechanical disruption, and mononuclear cells isolated by Ficoll centrifugation. Cryopreserved single-cell suspensions were thawed (>95% viable) and used immediately as targets in ADCC assays.
Human NK-cell NSG xenografts with Raji-luciferase cells
Raji cells expressing a luciferase-eGFP fusion were generated by spinfection of a Luc-eGFP-cassette-containing U3 retrovirus, followed by flow sorting of stable GFP-positive cells, as described (29) . The NSG-Raji model was chosen to examine the impact of ALT-803 administration on human NK-cell anti-CD20 mAbdirected clearance of human lymphoma cells in vivo. NSG mice were irradiated (250 cGy) 24 hours prior to i.v. injection with 1 Â 10 6 Raji-luciferase cells. After 3 days, human NK cells were injected (4 Â 10 6 /mouse, retro-orbital). Concurrently, 10 mg/kg rituximab and ALT-803 were injected i.v. Where indicated, ALT-803 or PBS (control) was administered i.v. twice weekly. Tumor burden was assessed by bioluminescence imaging (BLI). For BLI, mice were injected i.p. with 150 mcg/g D-luciferin (Biosynth) in PBS, anesthetized, and imaged with a CCD camera (IVIS 100; PerkinElmer); exposure time 1 to 60 seconds, binning 16, field of view 12, f/stop 1, open filter. Both dorsal and ventral whole body BLI images were taken and quantified as photon flux (29). Mice were also followed for survival, and euthanized when any unacceptable morbidity developed.
SCID mice with Daudi models
This second model was chosen to examine the impact of ALT-803 administration on mouse NK-cell anti-CD20 mAb-directed clearance of human lymphoma cells in vivo. SCID mice were injected i.v. with 1 Â 10 7 Daudi cells, and at day 15 randomized into the indicated treatment groups. Mice were injected with rituximab (10 mg/kg) and ALT-803 or controls on days 15 and 18. On day 22, the percentage of HLA-DR þ Daudi cells in femur bone marrow was determined using flow cytometry. For survival experiments, hind limb paralysis was used as the endpoint.
Statistical analysis
Statistical comparisons were performed using Student t test, Kruskal-Wallis test, ANOVA, and Kaplan-Meier analysis (Logrank, Mantel-Cox) as appropriate (Prism v5, GraphPad Software). For all testing, significance levels required P < 0.05.
Results
ALT-803 stimulation augments human NK-cell cytotoxicity and granzyme B and perforin expression
To determine whether initial findings that ALT-803 augmented murine NK-cell function (24, 25) is applicable to humans, we first defined the impact of short-term stimulation with ALT-803 on human NK-cell cytotoxicity against the MHC class I low, NK-cellsensitive target K562. Purified (>95% CD56 þ CD3 À ) human NK cells were stimulated with varying equimolar concentrations of ALT-803 or rhIL-15 for 20 hours, washed, and used as effector cells in a 4-hour cytotoxicity assay against K562 targets. ALT-803 and rhIL-15 enhanced human NK-cell killing in a comparable, dosedependent fashion ( Fig. 1A and B) . We next investigated the impact of short-term ALT-803 stimulation on key effector proteins that mediate NK-cell killing. ALT-803 induced a dose-dependent increase in the expression of perforin and granzyme B by CD56 dim human NK cells (Fig. 1C ). In addition, NK-cell stimulation was also evident via induction of the early activation marker CD69 ( Fig. 1D and E ). These data demonstrate that ALT-803, comparably with rhIL-15, enhances the cytotoxic potential and activation state of human NK cells in vitro.
ALT-803 augments NK-cell ADCC directed by an anti-CD20 mAb in vitro
ADCC represents a specialized NK-cell attack against mAbcoated target cells, and depends primarily on triggering via FcgRIIIa. We next tested the ability of short-term ALT-803 stimulation to enhance ADCC against the CD20 ALT-803 primes NK-cell ADCC and cytotoxicity against primary follicular lymphoma cells isolated from patient lymph nodes Purified normal donor NK cells were stimulated with ALT-803 for 20 hours, and used as effector cells in killing assays against primary follicular lymphoma target cells. The specific death of light-chain restricted CD19
þ clonal B cells were identified by CFSE labeling and CD19 surface staining. A representative donor is shown in Fig. 2D , demonstrating ALT-803 enhancement of both ADCC (rituximab) and NK cytotoxicity (control mAb) against these primary lymphoma target cells. This finding was reproducible between multiple lymphoma samples (Supplementary Table S1 ) and NK-cell donors (Fig. 2E) . Thus, ALT-803 also enhances primary human NK-cell killing of primary lymphoma cells in vitro.
ALT-803 enhances NK-cell IFNg production and degranulation triggered by anti-CD20 mAb-coated tumor cells To further define the impact of ALT-803 on NK-cell responses to mAb-opsonized target cells, we also examined NK-cell IFNg production and degranulation. Purified NK cells were stimulated for 20 hours with ALT-803, washed, and then cocultured for 6 hours with Raji target cells that were preincubated with rituximab or control mAb. ALT-803 prestimulation resulted in a dose-dependent enhancement of both IFNg production and degranulation (CD107a surface expression) in response to rituximab-coated Raji cells (Fig. 3A) . In addition, ALT-803 enhanced IFNg production and degranulation to a modest degree in the control-mAb conditions, especially at its maximal concentration. The mature CD57 þ subset of CD56 dim NK cells has been reported to exhibit enhanced FcgRIIIa-triggered IFNg production and redirected killing responses (30) . We therefore evaluated these NK-cell functional readouts, stratified by CD57 expression, following ALT-803 stimulation. We unexpectedly observed no impact of CD57 expression on NK-cell IFNg responses to FcgRIIIa-triggering via rituximab-coated Raji cells, while degranulation was significantly (albeit modestly) greater in the CD57 À less mature subset (Fig. 3B) . Collectively, these data reveal that ALT-803 enhances multiple NK-cell effector responses, including degranulation, cytotoxicity, ADCC, and IFNg production triggered by FcgRIIIa. ÃÃ , P < 0.01; ÃÃÃ , P < 0.001.
ALT-803 augments rituximab-directed clearance of Daudi lymphoma cells in SCID mice
Prior studies with ALT-803 have demonstrated its capacity to expand murine NK cells in mice (24, 25) . Here, 1 Â 10 7 Daudi lymphoma cells were engrafted into SCID mice on day 0, and mice were treated with vehicle (PBS), rituximab (R), ALT-803, or ALT-803 plus rituximab in two doses on day 15 and day 18 post-Daudi cell challenge (Fig. 4A) . First, the Daudi cell burden in the bone marrow of mice was examined at day 22 after challenge ( Fig. 4B  and C) . As shown in Fig. 4B , there was a significant enhancement of rituximab-mediated Daudi cell clearance in the bone marrow at all doses of ALT-803 tested. These results were confirmed in an additional experiment, albeit with lower overall Daudi cell engraftment (Fig. 4C) . To further assess the control of Daudi cells in vivo, groups of SCID mice were treated as in Fig. 4A and followed for survival. There was significantly enhanced survival of SCID mice treated with ALT-803 plus rituximab, compared with rituximab alone, or other conditions (Fig. 4D) . In separate experiments, the ability of rhIL-15 and ALT-803 were compared for their ability to augment rituximab-directed antilymphoma responses (Fig. 4E ) Equivalent doses and schedule of ALT-803 plus rituximab demonstrated significantly reduced Daudi cell burden compared with rhIL-15 plus rituximab. NK-cell numbers and percentages in the bone marrow of mice treated with ALT-803 and/or rituximab in Fig. 4B and C are shown in Fig. 4F and G. Overall, there was no biologically significant alteration in bone marrow NK-cell numbers or percentages with ALT-803 treatment in two doses in this model, suggesting that enhanced tumor clearance is due to NK-cell activation, as opposed to increased numbers. NKcell analyses in the spleen of the mice are provided in Supplementary Fig. S1 . This analysis was performed at day 22 at the time of Daudi cell examination, and only provides information as to the NK-cell modulation at this single time point. These findings demonstrate that ALT-803 enhances anti-CD20-directed control of Daudi B cell lymphoma in vivo.
ALT-803 enhances rituximab-directed control of Raji lymphoma cells in a human NK-cell NSG xenograft model
We next investigated the ability of ALT-803 administration to enhance human NK-cell clearance of lymphoma cell lines in vivo in conjunction with rituximab in an immunodeficient NSG mouse xenograft system. NSG mice were injected with Raji cells expressing luciferase, and groups of mice were treated with human NK cells and rituximab or control mAb on day 3, followed by ALT- (Fig. 5B) . Notably, although mice treated with human NK cells and rituximab exhibited tumor control for 2 weeks, there was significantly lower tumor cell burden measured by BLI in human NK cell plus ALT-803 plus rituximab-treated mice (Fig. 5B) . In a separate experiment, the reduced Raji cell burden in the human NK cell plus ALT-803 plus rituximab group, compared with human NK cells plus rituximab group, was confirmed (Fig. 5C) . In this NSG model of human NK-cell engraftment and ALT-803 therapy, we verified that human NK cells were present in the blood, spleen, and bone marrow of NSG mice at day 12 in both ALT-803 and control groups (data not shown). Human NK-cell-engrafted mice treated with ALT-803 plus rituximab had significantly prolonged survival compared with rituximab alone in this model (Fig. 5D) . Finally, when equivalent doses and schedules of rhIL-15 and ALT-803 were compared in combination with rituximab, ALT-803 plus rituximab exhibited significantly improved Raji lymphoma cell control in vivo (Fig. 5E) . In our NSG model, there exists the possibility that murine macrophages contribute to antitumor responses following anti-CD20 mAb treatment, which would require macrophage-depleting experiments to definitively address.
The impact of ALT-803 treatment on human NK cells transferred into NSG mice was also investigated (Supplementary Fig.  S2 ). Nine days after transfer, ALT-803-treated mice demonstrated increased human NK-cell numbers in the blood and liver, equivalent numbers in the bone marrow, and reduced engraftment in the spleen, compared with control mice ( Supplementary Fig. S2A  and S2B) (Fig. 6A) . However, chronic ALT-803 stimulation induced the emergence of a CD56 bright CD16 þ NK-cell subset after 1 to 2 weeks (Fig. 6A) The current standard-of-care treatments of iNHL rely primarily on nonspecific cytotoxic chemotherapy agents that affect rapidly dividing cells and damage DNA, thereby yielding clinical remissions, but with the cost of substantial potential toxicity (1, 2, 5) . The effectiveness of anti-CD20 mAbs against lymphoma, including their significant improvement in long-term clinical outcomes for NHL patients, provides proof-of-principle that immune-based therapy has activity against NHL (31) . This clinical activity has spurred interest in developing immunotherapy combinations that eliminate chemotherapy altogether, especially for iNHL. For example, doublets of therapeutic mAbs have been investigated in relapsed/refractory iNHL (32, 33) . In addition, the immunomodulatory (IMiD) drug lenalidomide has been shown to enhance NK-cell ADCC (34) , and when combined with rituximab has provided promising activity in patients with indolent (35, 36) , or subsets of aggressive, B-cell NHL (37) . Other cytokines (IL2, IL12, and HLA-DR expression. Additional early-phase clinical trials with rhIL-15 are ongoing that include subcutaneous administration (NCT01727076) for solid tumor patients, and i.v. rhIL-15 in metastatic carcinoma (NCT01572493) or following NK-cell infusion for myeloid diseases (NCT01385423). ALT-803 administered weekly is also currently being tested in phase I dose-escalation studies in advanced solid tumors (NCT01946789), relapse following allogeneic stem cell transplantation (NCT01885897), relapsed/refractory multiple myeloma (NCT02099539), and non-muscle invasive bladder cancer in combination with BCG (NCT02138734). Thus, available safety and correlative biological data suggest that IL-15 receptor engaging drugs may be safely administered with substantial in vivo human NK-cell modulation. As our data indicate that such IL-15-based modulation may be combined with anti-CD20 mAbs to enhance the innate immune response against B-cell lymphomas, clinical investigation of ALT-803 plus anti-CD20 mAbs in patients with iNHL is underway (NCT02384954). The large number of ongoing studies with rhIL-15 and ALT-803 will expand our understanding of whether these two agents will exhibit comparable or distinct immune modulation based on pharmacokinetics or in vivo distribution and will assist in the design of future clinical studies.
There are a number of potential mechanisms whereby ALT-803 may enhance antitumor immune responses to lymphoma. In our experiments examining ALT-803 enhancement of human NK-cell function, we observed comparable effects of equimolar concentrations of rhIL-15 and ALT-803 in vitro when examining cytotoxicity, ADCC, FcgRIIIa-triggered degranulation and IFNg production, and proliferation. These findings suggest that prior studies demonstrating that rhIL-15 augments direct NK-cell antitumor responses via a pleiotropic array of functional antitumor improvements (14, (17) (18) (19) , will also apply to ALT-803. However, in vivo ALT-803-induced NK-cell activation has been demonstrated to be superior to rhIL-15 (25) , as ALT-803 exhibits a greater serum halflife (24) , and prolonged distribution to lymphoid organs compared with rhIL-15 (Wong HC and colleagues, In Press, Cancer Immunology Research). In addition, stimulation of NK cells by therapeutic mAbs has been linked to "exhaustion" after triggering via FcgRIIIa through depletion of the cytotoxic effector molecules perforin and granzyme B (52) . Notably, signals through the IL2/15Rbg c reversed the cytotoxic effector molecule depletion, and allowed for effective serial NK-cell killing. We therefore expect that ALT-803 stimulation may reverse FcgRIIIatriggered "exhaustion", providing a more sustained NK-cell ADCC response when used in combination with therapeutic mAbs. While not directly examined in our study, IL-15 (18) and ALT-803 (25) have been shown to promote CD8 þ T-cell responses, resulting in enhanced T-cell-dependent antitumor immunity. As rituximab has been shown to induce an endogenous adaptive immune response in the setting of indolent NHL (53, 54) , ALT-803 therapy may also potentiate such autologous CD8 þ Tcell antitumor immunity. This effect may be further enhanced by coengagement of NK cells via anti-CD20 mAbs, resulting in NK-cell-derived cytokine production and DC activation and maturation. Thus, provision of ALT-803 plus rituximab may have additional favorable antitumor effects by promoting endogenous tumor-specific memory CD8 þ T-cell responses to lymphoma as has been shown in models of multiple myeloma (25) , in addition to directly augmenting NK-cell anti-CD20 triggered responses. In summary, we report that the immunostimulatory agent ALT-803 augments NK-cell proliferation, cytotoxic capacity, FcgRIIIa-triggered degranulation, and IFNg production, and ADCC against B-cell lymphoma. Furthermore, ALT-803 potentiated anti-CD20 mAb-directed tumor clearance of mice challenged with B-cell lymphoma lines in vivo. These preclinical results suggest that the combination of ALT-803 plus an anti-CD20 mAb merits testing in early-phase clinical trials in patients with iNHL in varying settings, including relapsed/ refractory disease, high-risk iNHL disease in remission, or iNHL patients with evidence of minimal residual disease. Moreover, investigations of IL-15-based immunostimulation plus therapeutic mAbs in multiple cancer types are warranted.
